

Back on growth track


14 June 2010 | News

image not found or type unknown



18

image not found or type unknown




Head:

Dr Bharat Daftary (CMD)

Business:

R&D, manufacturing and
marketing of biological,
pharmaceutical and

image not found or type unknown



Startup Year:
1971

Address:
Hoechst House, 16th Floor,
Nariman Point, Mumbai-400021,
Maharashtra

Tel:
+91-22-66560900

Fax:
+91-22-66560901

Website:
www.bharatserums.com

Fiscal 2009-10 saw Bharat Serums and Vaccines (BSV) registering a growth of 25 per cent clocking a total sales turnover of Rs 175 crore as against Rs 140 crore in fiscal 2008-09. The BSV registered a good growth as against the industry growth of 16 percent

BSV has received funding from the Malaysian firm OrbiMed to facilitate the next stage of growth. "Investment in BSV by one of the largest healthcare focused funds validates our company's research, manufacturing and marketing capabilities and distinctive business model. OrbiMed's investment and involvement will considerably facilitate the next stage of BSV's growth," stated Bharat Daftary, chairman and managing director

"BSV continues to be at the forefront of proprietary research of value added therapeutics and the investment by a knowledgeable investor like OrbiMed acts a booster for our self belief, long term value generation and growth prospects," Dr

The company manufactures and markets biological, pharmaceutical and biotechnology products and has in its portfolio over 25 brands which includes Plasma Derivatives, Monoclonals, Equine Antitoxins And Serums, Cardiovascular, Antimicrobials, Antifungals, Anesthetics, Hormones. Over the years, BSV has put in emphasis on its R&D operations both in India and overseas. It has three distinct R&D divisions working on human and equine products.

In April 2010, Piramal Healthcare Limited, acquired BSV's injectible anesthetic products business. The former signed a definitive agreement to acquire the Pune-based Bharat Serum's injectible anaesthetic products business including "propofol, bupivacaine and

BSV holds a significant market share in India for plasma derivatives. The product portfolio comprises a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums, antifungals, anaesthetics, cardiovascular and

BSV has allocated substantial resources towards the research and development of pharmaceutical products in the areas of Novel Drug Delivery, Biotechnology and Biologicals. BSV has a pipeline of novel products and "difficult generics" and is in the process of commercialization of these products.

The novel products include certain New Biological Entities and Novel Drug Delivery products will belong to BSV.

The anti-infective product is from the drug delivery research and comes under the category of difficult generics. BSV is seeking various partnering models including licensing, co-development, to commercialize its products.